Patents by Inventor Elisabeth Douglas Galsgaard

Elisabeth Douglas Galsgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416374
    Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
    Type: Application
    Filed: May 23, 2023
    Publication date: December 28, 2023
    Inventors: KALLE SOEDERSTROEM, ELISABETH DOUGLAS GALSGAARD
  • Patent number: 11697687
    Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: July 11, 2023
    Assignee: NOVO NORDISK A/S
    Inventors: Kalle Soederstroem, Elisabeth Douglas Galsgaard
  • Publication number: 20200268835
    Abstract: The present invention relates to compounds for use in the prevention and/or treatment of NASH. The present invention further relates to a method of preventing and/or treating NASH by administering to a subject in need thereof a compound of the invention. Compounds of the invention have been shown to be effective in reducing the relative liver weight (as percentage of total body weight), steatosis, inflammation in the liver and fibrogenesis in the liver.
    Type: Application
    Filed: June 13, 2019
    Publication date: August 27, 2020
    Inventors: Jesper F. Lau, Thomas Kruse, Dorte Holst, Elisabeth Douglas Galsgaard, Jenny Louise Egecioglu Norlin
  • Publication number: 20200109206
    Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 9, 2020
    Inventors: KALLE SOEDERSTROEM, ELISABETH DOUGLAS GALSGAARD
  • Publication number: 20170073417
    Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 16, 2017
    Inventors: KALLE SOEDERSTROEM, ELISABETH DOUGLAS GALSGAARD
  • Patent number: 9512228
    Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: December 6, 2016
    Assignee: NOVO NORDISK A/S
    Inventors: Kalle Soederstroem, Elisabeth Douglas Galsgaard
  • Publication number: 20140161802
    Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
    Type: Application
    Filed: June 18, 2012
    Publication date: June 12, 2014
    Applicant: NOVO ALLE
    Inventors: Kalle Soederstroem, Elisabeth Douglas Galsgaard